Crohn’s disease Ulcerative colitis SONIC [7] COMMIT [9] UC-SUCCESS [8] IFX IFX + AZA IFX IFX + MTX IFX IFX + AZA Clinical remission (%) 44 57 78 76…
Fig. 13.1 (a) Relative risk by decade, Crohn’s disease. (b) Relative risk by decade, ulcerative colitis Non-melanoma Skin Cancer In the USA, NMSC is the most commonly diagnosed malignancy. NMSC…
Fig. 16.1 Mechanism of action of adhesion molecules in the intestinal endothelium and their blockage by anti-adhesion drugs Integrins involved in T-cell migration are leucocyte function-associated antigen 1 (LFA-1 or…
Assay type Advantages Disadvantages Commercial example in United States ELIS A • Ease of administration • Generally low cost • False positives • Interference in measuring antibodies in the presence of…
Time post-resection 1 year Clinical 0–44% Endoscopic 0–84% Surgical 4–25% 5 years Clinical 32% Endoscopic 55–77% Surgical 4–25% 10 years Clinical 52% Endoscopic 74% Surgical 12–57% Adapted from Connelly et…
Fig. 18.1 Practical strategies for improving safety of biologic therapies Choice of Biologic Agents There are eight FDA-approved biologic agents to treat IBD, generally indicated for patients with active disease…
Crohn’s disease Mechanism Ulcerative colitis Vedoli zumab (approved) Anti-integrin Vedolizumab (approved) Etrolizumab (phase III) Etrolizumab (phase III) PF-00547659 (phase II) PF-00547659 (phase II) Ozanimod (phase II) Sphingosine-1-phosphate inhibitor Ozanimod (phase…
© Springer International Publishing AG 2018Adam S. Cheifetz and Joseph D. Feuerstein (eds.)Treatment of Inflammatory Bowel Disease with Biologics https://doi.org/10.1007/978-3-319-60276-9_12 12. Infectious Complications of Biologics Renée M. Marchioni Beery1 and Joshua R. Korzenik1 (1) Division of Gastroenterology, Hepatology, and…
© Springer International Publishing AG 2018Adam S. Cheifetz and Joseph D. Feuerstein (eds.)Treatment of Inflammatory Bowel Disease with Biologics https://doi.org/10.1007/978-3-319-60276-9_11 11. Biologic Therapy in Pediatric Inflammatory Bowel Disease Sonal Patel1 and Jennifer Strople1 (1) Division of Pediatric…
Authors Number of participants (n) Study design Relapse rate Significant predictors of relapse Predictors evaluated but not found to be significant Recapture rate CD Brooks et al. [52] 86…
